We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Barbara Burtness

Barbara Burtness MD

Professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Director, Developmental Therapeutics Research Program, Yale Cancer Center, New Haven, Connecticut
Dr Barbara Burtness is Professor of Medicine at the Yale University School of Medicine. She is co-leader of the Developmental Therapeutics Program, and director of the Head and Neck Clinical Research Program at Yale Cancer Center. Dr Burtness graduated with an MD from SUNY at Stonybrook. She completed internship and residency at Yale-New Haven Hospital and fellowship training in oncology at Memorial Sloan Kettering Cancer Center. 

Dr Burtness’ research focuses on clinical trials of immunotherapy and translational studies of resistance to immunotherapy and EGFR inhibition, and synthetic lethal approaches for HPV negative head and neck cancer. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multi-center trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers. She has conducted numerous phase I–III investigator-initiated trials. 

Dr Burtness co-edits the text Molecular Determinants of Head and Neck Cancer, and is editor-in-chief of the journal Cancers of the Head and Neck. Her research has been published in numerous peer-reviewed journals, including the Lancet, Journal of Clinical Oncology, Lancet Oncology, and Clinical Cancer Research.